Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number Accreditation/Credit Designation Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-9999-20-356-H01-P.

Acknowledgment of Support

This activity is supported by educational grants from AbbVie and Celgene Corporation.

Oncology Consultations®: Clinical Conversations Between an Oncology Nurse and Pharmacist During AML Treatment

Release Date: October 26, 2020
Expiration Date: October 26, 2021

Activity Overview

For nearly 40 years, clinicians treating patients with acute myeloid leukemia (AML) had few new treatment options. However, 2017 and 2018 were watershed years in terms of new approvals, with 8 medications approved for treatment of AML and several additional agents involved in phase 3 trials during these years. These new agents promise substantial benefits for patients with AML and offer new treatment options for health care teams. This expanding arsenal of therapies allows practitioners to hone treatment and individualize care. While novel therapies and combinations benefit patients with AML, they also add markedly to the complexity of the treatment decision-making process for a patient population with many medical comorbidities.

This Oncology Consultations® activity is a video-based program in which 2 experts use a case-based approach to discuss the treatment and management of AML. In this activity, the faculty focus on a comprehensive review of novel and emerging therapies for the management of AML in patients who are fit for intensive induction therapy and patients who are not eligible for intensive therapy, applying recent trial data to clinical practice and providing insight into the future of AML management. This engaging format is designed to help clinicians identify best practices in the management of AML and to improve outcomes for their patients with this disease.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie and Celgene Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This activity is directed toward oncology nurses and hematology/oncology pharmacists who manage and treat patients with acute myeloid leukemia.

Pharmacists seeking credit should visit: https://www.pharmacytimes.org/on-demand/clinical-conversations-between-an-oncology-nurse-and-pharmacist-during-aml-treatment to participate in this activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Distinguish treatment approaches for acute myeloid leukemia (AML) based on disease- and patient-specific factors
  • Interpret clinical trial data of approved and emerging treatment options in AML to optimize patient care and ensure appropriate patient management
  • Identify strategies for prevention and management of adverse effects associated with treatments used in AML
  • Examine approaches to improve outcomes for patients with AML, emphasizing multidisciplinary care with nursing and pharmacist team members

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Craig W. Freyer, PharmD, BCOP
Craig W. Freyer, PharmD, BCOP
Clinical Pharmacy Specialist in Hematology/Oncology,
Stem Cell Transplant, and Cellular Therapy
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Consultant: Astellas Pharma, Incyte, Servier; Speakers Bureau: Astellas Pharma (Infectious Diseases Speakers Bureau)

Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Nurse Practitioner
Associate Clinical Professor
University of California San Francisco
San Francisco, CA

Disclosures: Consultant: Merck

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
2930
Filter By